


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shandong Extreme Vision Technology Co., Ltd.*

山東極視角科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6636)

**(I) PROPOSED AMENDMENTS TO THE ARTICLES OF
ASSOCIATION;
(II) PROPOSED REVOCATION OF
EXISTING GENERAL MANDATE TO ISSUE SHARES
AND GRANT OF NEW GENERAL MANDATE TO ISSUE SHARES;
AND
(III) PROPOSED CAPITAL INJECTION IN A WHOLLY-OWNED
SUBSIDIARY**

The board (the “**Board**”) of directors (the “**Directors**”) of Shandong Extreme Vision Technology Co., Ltd.* (the “**Company**”) hereby announces that on September 24, 2026, the Board resolved to (i) make certain amendments to the articles of association of the Company (the “**Articles of Association**”); (ii) revoke the general mandate to issue shares granted to the Board at the annual general meeting of the Company held on June 11, 2026 (the “**Existing Issue Mandate**”) and to grant a new general mandate to the Board to allot, issue and deal with additional shares (including any sale or transfer of treasury shares), or securities convertible into shares or options, warrants or similar rights to subscribe for shares or such convertible securities (the “**New Issue Mandate**”); and (iii) make capital injection in Zhuhai Hengqin Extreme Vision Technology Co., Ltd.* (珠海橫琴極視角科技有限公司) (“**Hengqin Extreme Vision**”), a wholly-owned subsidiary of the Company.

I. PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Reference is made to the announcement dated August 26, 2026 of the Company in relation to the proposed implementation and application of the H share full circulation (the “**H Share Full Circulation**”).

To reflect the changes in the Company's equity structure following the completion of the H Share Full Circulation, the Board proposed to make certain amendments to the Articles of Association (the "**Proposed Amendments**"), details of which are set out below.

Before amendments	After amendments
Article 3 The Company completed the filing with the China Securities Regulatory Commission (the "CSRC") on January 14, 2026, and conducted its initial public offering of 12,480,000 overseas listed shares ("H Shares"), wherein the Company's shareholders converted part of their 99,872,436 aggregate domestically non-listed shares into H Shares. Such H Shares were listed on The Stock Exchange of Hong Kong Limited (the "SEHK") on March 30, 2026. Shares that have been issued by the Company but are not listed or traded on any domestic or overseas stock exchange are referred to as domestic unlisted shares. After the Company issues shares overseas and lists them, and where permitted by the relevant laws, administrative regulations and departmental rules, shareholders holding the Company's domestic unlisted shares may convert such shares into H Shares for listing and trading on overseas stock exchanges. Such shares as are listed and traded on an overseas stock exchange shall also comply with the regulatory procedures, rules and requirements of both the domestic and overseas securities markets. The conversion of the aforesaid domestic unlisted shares into H Shares and their subsequent listing and trading on an overseas stock exchange shall not require a resolution to be passed at a shareholders' meeting.	Article 3 The Company completed the filing with the China Securities Regulatory Commission (the "CSRC") on January 14, 2026, and conducted its initial public offering of 12,480,000 overseas listed shares ("H Shares"), wherein the Company's shareholders converted part of their 99,872,436 aggregate domestically non-listed shares into H Shares. Such H Shares were listed on The Stock Exchange of Hong Kong Limited (the "SEHK") on March 30, 2026. <u>The Company completed filing with the CSRC on [date]. [•] domestic unlisted shares of the Company were converted into H Shares and listed on the SEHK on [date].</u> Shares that have been issued by the Company but are not listed or traded on any domestic or overseas stock exchange are referred to as domestic unlisted shares. After the Company issues shares overseas and lists them, and where permitted by the relevant laws, administrative regulations and departmental rules, shareholders holding the Company's domestic unlisted shares may convert such shares into H Shares for listing and trading on overseas stock exchanges. Such shares as are listed and traded on an overseas stock exchange shall also comply with the regulatory procedures, rules and requirements of both the domestic and overseas securities markets. The conversion of the aforesaid domestic unlisted shares into H Shares and their subsequent listing and trading on an overseas stock exchange shall not require a resolution to be passed at a shareholders' meeting.

Before amendments	After amendments
Article 18 After the Company's completion of the initial public offering of H Shares, the Company's total share capital will be 112,914,783 shares, all of which will be ordinary shares. This consists of 562,347 domestic unlisted shares, accounting for 0.50% of the Company's total share capital; and 112,352,436 H Shares (ordinary shares), accounting for 99.50% of the Company's total share capital.	Article 18 After the Company's completion of the initial public offering of H Shares, the Company's total share capital <u>is</u> 112,914,783 shares, all of which <u>are H Shares (ordinary shares), with no domestic unlisted shares.</u>

Save for the amendments as set out above, other provisions of the currently effective Articles of Association remain unchanged.

The Board has considered and passed the resolution on the Proposed Amendments, and will submit the Proposed Amendments to the shareholders of the Company (the “**Shareholder(s)**”) for their consideration and approval. The Board also requests the Shareholders' meeting of the Company to authorize the Board and person authorized by the Board to handle matters relating to the Proposed Amendments, including but not limited to making adjustments and changes to the Articles of Association approved by Shareholders in the Shareholders' meeting according to the requirements and recommendations of domestic and overseas regulatory authorities, and handling change registration with the company registration authorities and other relevant departments.

The Proposed Amendments shall take effect from the date of the completion of the H Share Full Circulation, subject to approval by the Shareholders at the extraordinary general meeting to be convened by the Company in due course (the “**EGM**”). Prior to the effectiveness of the amended Articles of Association, the prevailing Articles of Association shall remain effective. The final amendments to the Articles of Association shall be subject to the filing with the competent authority for market regulation.

II. PROPOSED REVOCATION OF EXISTING ISSUE MANDATE AND GRANT OF NEW ISSUE MANDATE

Reference is made to the circular of the Company's annual general meeting dated May 21, 2026 in relation to the Existing Issue Mandate.

In order to ensure flexibility and discretion to the Board to issue new shares as and when desirable and appropriate, a special resolution will be proposed at the EGM to revoke the Existing Issue Mandate and to grant the New Issue Mandate to the Board

to allot, issue and deal with additional shares (including any sale or transfer of treasury shares), or securities convertible into shares or options, warrants or similar rights to subscribe for shares or such convertible securities not exceeding 20% of the total number of shares (excluding treasury shares) in issue as at the date of passing such resolution.

III. PROPOSED CAPITAL INJECTION IN A WHOLLY-OWNED SUBSIDIARY

The Board has considered and passed the resolution on the proposed capital injection (the “**Capital Injection**”) of RMB138.0 million by the Company in Hengqin Extreme Vision. Upon completion of the Capital Injection, the Company will continue to hold 100% equity interest in Hengqin Extreme Vision. The amount of the Capital Injection will be paid by the Company’s own funds.

The Directors are of the view that the Capital Injection will help Hengqin Extreme Vision strengthen its capital strength and consolidate the foundation for development, enhance its market competitiveness and achieve sustainable development. The Directors therefore believe that the Capital Injection is in the interests of the Company and its Shareholders as a whole and will bring strategic benefits to the Group in the long run.

The Capital Injection does not constitute any notifiable transaction of the Company under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) or connected transaction of the Company under Chapter 14A of the Listing Rules.

The Capital Injection is subject to the approval of the Shareholders pursuant to Article 39 of the Articles of Association.

IV. GENERAL

The EGM will be convened to consider and, if thought fit, approve (i) the Proposed Amendments, (ii) the proposed revocation of the Existing Issue Mandate and the grant of the New Issue Mandate, and (iii) the proposed Capital Injection. A circular containing, among other things, details of the above resolutions, together with the notice of EGM, will be despatched to the Shareholders (if requested) and published on the websites of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and the Company (www.extremevision.com.cn) in due course.

By order of the Board
Shandong Extreme Vision Technology Co., Ltd.*
Mr. CHAN Chan Kit
Chairman, Executive Director and General Manager

Hong Kong, September 24, 2026

As at the date of this announcement, the Board comprises Mr. CHAN Chan Kit, Ms. LUO Yun, Mr. CHEN Shuo as executive Directors, Dr. NIU Baozhuang, Dr. LIU Shijie, Mr. LI Changzhen, Mr. CHEUNG Che Kit Richard as independent non-executive Directors.

* *For identification purpose only*